Merck KGaA

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

ExScientia Ltd

The U.S.-listed shares of Exscientia PLC EXAI soared 28.5% toward a record one-day gain, and enough to pace all premarket gainers on major U.S. exchanges, after the U.K.-based precision medicine company announced a collaboration with Germany-based Merck KGaA MKKGY XE:MRK for the discovery of drug candidates across oncology, neuroinflammation and immunology. The multi-year collaboration will utilize Exscientia's drug design and discovery capabilities, which are driven by use of artificial intelligence.

Exscientia's stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany's Merck KGaA

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company's research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., are expected to generate several novel clinical development drug candidates with first-in-class and best-in-class pote.

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

Merck KGaA reported disappointing Q2 results with a decrease in gross profit and EBIT compared to the previous year. The company remains confident in its 2025 targets despite reducing its full-year guidance for 2023. Anticipated double-digit revenue growth in 2024 and 2025 makes Merck a potential investment opportunity.

Merck KGaA: Expect A 10% CAGR EBITDA Increase In 2024-2025

Merck KGaA (OTCPK:MKGAF) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - Chief Executive Officer Helene von Roeder - Chief Financial Officer Matthias Heinzel - Chief Executive Officer of Life Science Peter Guenter - Chief Executive Officer of Healthcare Kai Beckmann - Chief Executive Officer of Electronics Conference Call Participants Richard Foster - J.P. Morgan Matthew Weston - Credit Suisse Sachin Jain - Bank of America James Quigley - Morgan Stanley Michael Leuchten - UBS Gary Stevenson - BNP Paribas Peter Verdult - Citi Oliver Metzger - Oddo BHF Simon Baker - Redburn Dylan van Haaften - Stifel Nicolaus Rajesh Kumar - HSBC Constantin Fest Thank you very much Sharon, a very warm welcome to this Merck Q2 2023 Results Call.

Merck KGaA (MKGAF) Q2 2023 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - Chair of the Executive Board and Chief Executive Officer Marcus Kuhnert - Chief Financial Officer Peter Guenter - Chief Executive Officer, Healthcare Matthias Heinzel - Chief Executive Officer, Life Science Kai Beckmann - Chief Executive Officer, Electronics Helene von Roeder - Chief Financial Officer Conference Call Participants Matthew Weston - Credit Suisse Sachin Jain - Bank of America Gary Steventon - Exane BNP Paribas Peter Verdult - Citigroup Falko Friedrichs - Deutsche Bank Oliver Metzger - ODDO BHF Bank Simon Baker - Redburn Partners Florent Cespedes - Societe Generale Matthew Weston - Credit Suisse Operator Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on the First Quarter 2023. As a reminder, all participants will be in a listen-only mode.

Merck KGaA (MKGAF) Q1 2023 Earnings Call Transcript

Merck KGaA: A German Free Cash Flow Machine

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, which operates its Healthcare business as EMD Serono in the US and Canada, today announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO® (avelumab) following the termination of its Alliance agreement with Pfizer.

Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)

MERCK Kommanditgesellschaft auf Aktien (OTCPK:MKGAF) Q4 2022 Results Earnings Conference Call March 2, 2023 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - Chair of the Executive Board and Chief Executive Officer Marcus Kuhnert - Chief Financial Officer Peter Guenter - Chief Executive Officer, Healthcare Matthias Heinzel - Chief Executive Officer, Life Science Kai Beckmann - Chief Executive Officer, Electronics Conference Call Participants Sachin Jain - Bank of America Richard Vosser - J.P. Morgan Matthew Weston - Credit Suisse Keyur Parekh - Goldman Sachs Michael Leuchten - UBS Peter Verdult - Citigroup Gary Steventon - Exane BNP Paribas Rosie Turner - Jefferies James Quigley - Morgan Stanley Falko Friedrichs - Deutsche Bank Oliver Metzger - ODDO BHF Bank Simon Baker - Redburn Partners Operator Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on the Fourth Quarter 2022.

MERCK Kommanditgesellschaft auf Aktien (MKGAF) Q4 2022 Results - Earnings Call Transcript

AbbVie

Abbott Labs

Becton, Dickinson and Co.

Bruker

Danaher

DexCom

Edwards Lifesciences

Medtronic

Thermo Fisher Scientific

The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.

Ranking The Diversified Healthcare Giants

Big pharma performed well in 2022, but the time to trim is drawing close. As a more diversified investment, I believe former parent company of Merck & Co, Merck KGaA offers a better long-term investment.

Trim Big Pharma For Merck KgaA

DARMSTADT, Germany--( BUSINESS WIRE )--Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its Healthcare business as EMD Serono in the US and Canada, today shared updates on the company's healthcare research and development strategy, aimed at doubling R&D productivity. To achieve the goal of introducing one new product or major indication every 1.5 years on average, the company will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an increased focus on external innovation. The company expects to maintain the output of its internal discovery engine, while more than 50% of future launches will result from external co-development partnerships and strategic in-licensing of assets for further in-house development. The strategy was shared today at the company's R&D Update Call.

Merck KGaA, Darmstadt, Germany Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster

DARMSTADT, Germany--( BUSINESS WIRE )--Merck, a leading science and technology company, today shared updates on the company's healthcare research and development strategy, aimed at doubling R&D productivity. To achieve the goal of introducing one new product or major indication every 1.5 years on average, the company will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an increased focus on external innovation. The company expects to maintain the output of its internal discovery engine, while more than 50% of future launches will result from external co-development partnerships and strategic in-licensing of assets for further in-house development. The strategy was shared today at the company's R&D Update Call.

Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster

MERCK Kommanditgesellschaft auf Aktien (OTCPK:MKGAF) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Constantin Fest - Head, IR Belen Garijo - Group, CEO Marcus Kuhnert - Group CFO Matthias Heinzel - CEO, Life Science Kai Beckmann - CEO, Electronics Peter Guenter - CEO, Healthcare Conference Call Participants Rosie Turner - Jefferies Sachin Jain - Bank of America Peter Verdult - Citi Wimal Kapadia - Bernstein Gary Steventon - BNP Paribas Exane James Quigley - Morgan Stanley Michael Leuchten - UBS. Florent Cespedes - Societe Generale Falko Friedrichs - Deutsche Bank Simon Baker - Redburn Operator Ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on Third Quarter 2022.

MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q3 2022 Results - Earnings Call Transcript

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced findings which demonstrated that annualized relapse rates (ARR) remained low and Expanded Disability Status Scale (EDSS) scores were stable in people with relapsing multiple sclerosis (RMS) treated with investigational evobrutinib through more than three and half years.

Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Merck KGaA does not anticipate that a projected decline in smartphone sales this year will weigh on its semiconductor chemicals business any time soon, CEO Belen Garijo told Reuters on Thursday.

Germany's Merck KGaA insists semiconductor market remains attractive

NERVIANO, Italy--(BUSINESS WIRE)--Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck

Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293. NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293. NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or

Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

MERCK Kommanditgesellschaft auf Aktien (OTCPK:MKGAF) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Constantin Fest - Head, IR Belen Garijo - Group, CEO Marcus Kuhnert - Group CFO Matthias Heinzel - CEO, Life Science Peter Guenter - CEO, Healthcare Kai Beckmann - CEO, Electronics Conference Call Participants Richard Vosser - JPMorgan Matthew Weston - Credit Suisse Gary Steventon - BNP Paribas Peter Verdult - Citi Wimal Kapadia - Bernstein Sachin Jain - Bank of America Operator Ladies and gentlemen to the Merck Investor and Analyst Conference Call for the second quarter of 2022. [Operator Instructions] I will now hand the call over to Constantin Fest, Head of Investor Relations, who will lead you through the conference.

MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q2 2022 Results - Earnings Call Transcript

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today provided an update on the progress of the company's innovative oncology development pipeline focused on DNA damage biology. With clinical programs designed to further advance standards of care in core tumors and assess the potential of novel mechanisms of action, including an industry-leading portfolio of DNA Damage Response inhibitors (DDRi), the company continues to build its focused leadership in the

Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the latest research representing the Company's innovative oncology portfolio has been accepted for presentation at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company's licensed medicines BAVENCIO® (

Merck to Present Latest Research From Oncology Portfolio at ASCO 2022

Merck KGaA (OTCPK:MKGAF) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - CEO of the Group Marcus Kuhnert - CFO Matthias Heinzel - CEO of Life Science Peter Guenter - CEO of Healthcare Kai Beckmann - CEO for Electronics Conference Call Participants Matthew Weston - Credit Suisse Richard Vosser - JPMorgan Gary Steventon - BNP Paribas Exane James Quigley - Morgan Stanley Sachin Jain - Bank of America Keyur Parekh - Goldman Sachs Falko Friedrichs - Deutsche Bank Daniel Wendorff - ODDO BHF Simon Baker - Redburn Florent Cespedes - Societe General Operator Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on the First Quarter 2022. [Operator Instructions] May I now hand you over to Constantin Fest, Head of Investor Relations, who will lead you through this conference.

Merck KGaA (MKGAF) CEO Belén Garijo on Q1 2022 Results - Earnings Call Transcript

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced 13 abstracts from the Company's multiple sclerosis (MS) portfolio will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, being held April 2-7. Data being presented include presentations on investigational Bruton's tyrosine kinase (BTK) inhibitor evobrutinib, including new 2.5-year efficacy and safety data in patients with relapsing multiple sclerosis (RMS) from a Phas

Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022

DARMSTADT, Germany--(BUSINESS WIRE)--The email addresses in the contacts section of the release dated November 22, 2021 03:00 AM Eastern Standard Time have been updated to: gangolf.schrimpf@emdgroup.com and investor.relations@emdgroup.com The updated release reads: MERCK KGAA, DARMSTADT, GERMANY HIGHLIGHTS NOVEL MECHANISMS WITH THE POTENTIAL TO TRANSFORM STANDARDS OF CARE IN SEVERAL CANCERS, MS, AND LUPUS 5 potential first-in-class assets aimed at delivering significant long-term growth 14 clin

CORRECTING and REPLACING: Merck KGaA, Darmstadt, Germany Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus

SAN FRANCISCO--(BUSINESS WIRE)---- $MKKGY #AI--Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials

News for Merck KGaA Stock (MKKGY)